Protocol No
OTO-SOUND-SPI-1005-401
Staff Member
Michael S Harris
Phase
III
Summary
This project is being done to find out if an investigational drug called SPI-1005 is safe in people with Meniere's Disease for 6 or 12 months to support long-term or repeated use.
Objective
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov